SAM
Sectoral Asset Management Portfolio holdings
AUM
$125M
1-Year Est. Return
68.15%
This Fund
S&P 500
1 Year Est. Return
+68.15%
AUM
$125M
AUM Growth
-$37.3M
(-23%)
Holding
88
Top Buys
| 1 | +$11.1M | |
| 2 | +$1.24M | |
| 3 | +$989K | |
| 4 |
Cogent Biosciences
COGT
|
+$919K |
| 5 |
Amgen
AMGN
|
+$866K |
Top Sells
| 1 | +$8.08M | |
| 2 | +$7.55M | |
| 3 | +$6.35M | |
| 4 |
AnaptysBio
ANAB
|
+$5.96M |
| 5 |
Immatics
IMTX
|
+$5.02M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
76
Bristol-Myers Squibb
BMY
$123B
| – | – |
-10,800
|
|
||
77
Cigna
CI
$73.5B
| – | – |
-1,800
|
|
||
78
MoonLake Immunotherapeutics
MLTX
$1.32B
| – | – |
-956
|
|
||
|
MRUS
79
DELISTED
Merus
MRUS
| – | – |
-11,545
|
|
||
80
Vaxcyte
PCVX
$8.97B
| – | – |
-4,205
|
|
||
81
Solid Biosciences
SLDB
$849M
| – | – |
-633,052
|
|
||
82
Instil Bio
TIL
$60.2M
| – | – |
-161,380
|
|
||
83
State Street SPDR S&P Biotech ETF
XBI
$8.94B
| – | – |
-34,000
|
|
||
84
Zai Lab
ZLAB
$2.73B
| – | – |
-12,590
|
|
||
|
BCAX
85
Bicara Therapeutics
BCAX
$1.57B
| – | – |
-266,495
|
|
||
|
MBX
86
MBX Biosciences
MBX
$1.6B
| – | – |
-194,898
|
|
||
|
ZBIO
87
Zenas BioPharma
ZBIO
$1.36B
| – | – |
-152,025
|
|
||
|
PVLA
88
Palvella Therapeutics
PVLA
$1.86B
| – | – |
-49,115
|
|